請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57177
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳漪紋(Yi-Wen Chen) | |
dc.contributor.author | Wei-An Shih | en |
dc.contributor.author | 施維安 | zh_TW |
dc.date.accessioned | 2021-06-16T06:36:59Z | - |
dc.date.available | 2019-10-09 | |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-07-31 | |
dc.identifier.citation | 1. Pihlstrom BL, Michalowicz BS, & Johnson NW (2005) Periodontal diseases. The Lancet 366(9499):1809-1820.
2. Tanner A, Maiden MF, Macuch PJ, Murray LL, & Kent RL, Jr. (1998) Microbiota of health, gingivitis, and initial periodontitis. Journal of Clinical Periodontology 25(2):85-98. 3. Michalowicz BS, et al. (2000) Evidence of a substantial genetic basis for risk of adult periodontitis. Journal of Periodontology 71(11):1699-1707. 4. Bergstrom J (2004) Tobacco smoking and chronic destructive periodontal disease. Odontology 92(1):1-8. 5. Glick M, Muzyka BC, Lurie D, & Salkin LM (1994) Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surgery, Oral Medicine, Oral Pathology 77(4):344-349. 6. Soskolne WA & Klinger A (2001) The relationship between periodontal diseases and diabetes: an overview. Annals of Periodontology 6(1):91-98. 7. Cobb CM (2002) Clinical significance of non-surgical periodontal therapy: an evidence-based perspective of scaling and root planing. Journal of Clinical Periodontology 29:22-32. 8. Hanes PJ & Purvis JP (2003) Local anti-infective therapy: pharmacological agents. A systematic review. Annals of Periodontology 8(1):79-98. 9. Bosshardt DD & Sculean A (2009) Does periodontal tissue regeneration really work? Periodontology 2000 51:208-219. 10. Engler WO, Ramfjord SP, & Hiniker JJ (1966) Healing following simple gingivectomy. A tritiated thymidine radioautographic study. I. Epithelialization. Journal of Periodontology 37(4):298-308. 11. Cortellini P & Tonetti MS (2000) Focus on intrabony defects: guided tissue regeneration. Periodontology 2000 22(1):104-132. 12. Gottlow J, Nyman S, Karring T, & Lindhe J (1984) New attachment formation as the result of controlled tissue regeneration. Journal of Clinical Periodontology 11(8):494-503. 13. Gottlow J, Nyman S, Lindhe J, Karring T, & Wennstrom J (1986) New attachment formation in the human periodontium by guided tissue regeneration. Case reports. Journal of Clinical Periodontology 13(6):604-616. 14. Bottino MC, et al. (2012) Recent advances in the development of GTR/GBR membranes for periodontal regeneration--a materials perspective. Dental Materials 28(7):703-721. 15. Gentile P, Chiono V, Tonda-Turo C, Ferreira AM, & Ciardelli G (2011) Polymeric membranes for guided bone regeneration. Biotechnology Journal 6(10):1187-1197. 16. Bunyaratavej P & Wang HL (2001) Collagen membranes: a review. Journal of Periodontology 72(2):215-229. 17. Behring J, Junker R, Walboomers XF, Chessnut B, & Jansen JA (2008) Toward guided tissue and bone regeneration: morphology, attachment, proliferation, and migration of cells cultured on collagen barrier membranes. A systematic review. Odontology 96(1):1-11. 18. Siemann U (2005) Solvent cast technology – a versatile tool for thin film production. Scattering Methods and the Properties of Polymer Materials, Progress in Colloid and Polymer Science, (Springer Berlin Heidelberg), Vol 130, pp 1-14. 19. Liao CJ, et al. (2002) Fabrication of porous biodegradable polymer scaffolds using a solvent merging/particulate leaching method. Journal of Biomedical Materials Research Part A 59(4):676-681. 20. Strathmann H & Kock K (1977) The formation mechanism of phase inversion membranes. Desalination 21(3):241-255. 21. Bottino MC, Thomas V, & Janowski GM (2011) A novel spatially designed and functionally graded electrospun membrane for periodontal regeneration. Acta Biomaterialia 7(1):216-224. 22. Al Mubarak SA, Karring T, & Ho A (2000) Clinical evaluation of subgingival application of metronidazole 25%, and adjunctive therapy. Journal of the International Academy of Periodontology 2(3):64-70. 23. Park YJ, et al. (2000) Enhanced guided bone regeneration by controlled tetracycline release from poly(L-lactide) barrier membranes. Journal of Biomedical Materials Research Part A 51(3):391-397. 24. Lee SB, et al. (2008) Surface modification of a guided tissue regeneration membrane using tetracycline-containing biodegradable polymers. Surface and Interface Analysis 40(3-4):192-197. 25. Cheng CF, Wu KM, Chen YT, & Hung SL (Bacterial adhesion to antibiotic-loaded guided tissue regeneration membranes – A scanning electron microscopy study. Journal of the Formosan Medical Association (0). 26. Zamani M, Morshed M, Varshosaz J, & Jannesari M (2010) Controlled release of metronidazole benzoate from poly ε-caprolactone electrospun nanofibers for periodontal diseases. European Journal of Pharmaceutics and Biopharmaceutics 75(2):179-185. 27. He CL, Huang ZM, & Han XJ (2009) Fabrication of drug-loaded electrospun aligned fibrous threads for suture applications. Journal of Biomedical Materials Research Part A 89(1):80-95. 28. Chen FM, Shelton RM, Jin Y, & Chapple IL (2009) Localized delivery of growth factors for periodontal tissue regeneration: role, strategies, and perspectives. Medicinal Research Reviews 29(3):472-513. 29. Kaigler D, Cirelli JA, & Giannobile WV (2006) Growth factor delivery for oral and periodontal tissue engineering. Expert Opinion on Drug Delivery 3(5):647-662. 30. Luginbuehl V, Meinel L, Merkle HP, & Gander B (2004) Localized delivery of growth factors for bone repair. European Journal of Pharmaceutics and Biopharmaceutics 58(2):197-208. 31. Ripamonti U & Renton L (2006) Bone morphogenetic proteins and the induction of periodontal tissue regeneration. Periodontology 2000 41:73-87. 32. Tatakis DN, et al. (2000) Periodontal repair in dogs: effect of transforming growth factor-beta 1 on alveolar bone and cementum regeneration. Journal of Clinical Periodontology 27(9):698-704. 33. Cooke JW, et al. (2006) Effect of rhPDGF-BB delivery on mediators of periodontal wound repair. Tissue Engineering 12(6):1441-1450. 34. Chen FM, et al. (2006) Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres. Journal of Controlled Release 114(2):209-222. 35. Takayama S, Murakami S, Shimabukuro Y, Kitamura M, & Okada H (2001) Periodontal regeneration by FGF-2 (bFGF) in primate models. Journal of Dental Research 80(12):2075-2079. 36. Schrier JA & DeLuca PP (1999) Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems. Pharmaceutical Development and Technology 4(4):611-621. 37. Blumenthal NM, et al. (2002) Effect of surgical implantation of recombinant human bone morphogenetic protein-2 in a bioabsorbable collagen sponge or calcium phosphate putty carrier in intrabony periodontal defects in the baboon. Journal of Periodontology 73(12):1494-1506. 38. Chen FM, et al. (2007) Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins. Journal of Controlled Release 121(1-2):81-90. 39. Fujisato T, Sajiki T, Liu Q, & Ikada Y (1996) Effect of basic fibroblast growth factor on cartilage regeneration in chondrocyte-seeded collagen sponge scaffold. Biomaterials 17(2):155-162. 40. Murphy WL, Peters MC, Kohn DH, & Mooney DJ (2000) Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 21(24):2521-2527. 41. Takahashi Y, Yamamoto M, Yamada K, Kawakami O, & Tabata Y (2007) Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 13(2):293-300. 42. Sato Y, Kikuchi M, Ohata N, Tamura M, & Kuboki Y (2004) Enhanced cementum formation in experimentally induced cementum defects of the root surface with the application of recombinant basic fibroblast growth factor in collagen gel in vivo. Journal of Periodontology 75(2):243-248. 43. Park YJ, Ku Y, Chung CP, & Lee SJ (1998) Controlled release of platelet-derived growth factor from porous poly(l-lactide) membranes for guided tissue regeneration. Journal of Controlled Release 51(2–3):201-211. 44. Lee SJ, et al. (2001) Molded porous poly (L-lactide) membranes for guided bone regeneration with enhanced effects by controlled growth factor release. Journal of Biomedical Materials Research Part A 55(3):295-303. 45. Rossa C, Jr., et al. (2000) Regeneration of Class III furcation defects with basic fibroblast growth factor (b-FGF) associated with GTR. A descriptive and histometric study in dogs. Journal of Periodontology 71(5):775-784. 46. Wikesjo UM, et al. (2003) Periodontal repair in dogs: evaluation of a bioabsorbable space-providing macroporous membrane with recombinant human bone morphogenetic protein-2. Journal of Periodontology 74(5):635-647. 47. Clark RF (1988) Overview and general considerations of wound repair. The Molecular and Cellular Biology of Wound Repair, eds Clark RAF & Henson PM (Springer US), pp 3-33. 48. Martin P (1997) Wound healing--aiming for perfect skin regeneration. Science 276(5309):75-81. 49. Wikesjo UME & Selvig KA (1999) Periodontal wound healing and regeneration. Periodontology 2000 19(1):21-39. 50. Wikesjo UM, Crigger M, Nilveus R, & Selvig KA (1991) Early healing events at the dentin-connective tissue interface. Light and transmission electron microscopy observations. Journal of Periodontology 62(1):5-14. 51. Grzesik WJ & Narayanan AS (2002) Cementum and periodontal wound healing and regeneration. Critical Reviews in Oral Biology and Medicine 13(6):474-484. 52. Haney JM, Nilveus RE, McMillan PJ, & Wikesjo UM (1993) Periodontal repair in dogs: expanded polytetrafluoroethylene barrier membranes support wound stabilization and enhance bone regeneration. Journal of Periodontology 64(9):883-890. 53. Sigurdsson TJ, Hardwick R, Bogle GC, & Wikesjo UM (1994) Periodontal repair in dogs: space provision by reinforced ePTFE membranes enhances bone and cementum regeneration in large supraalveolar defects. Journal of Periodontology 65(4):350-356. 54. Park YJ, et al. (1997) Porous poly(l-lactide) membranes for guided tissue regeneration and controlled drug delivery: membrane fabrication and characterization. Journal of Controlled Release 43(2–3):151-160. 55. Cabrera C, Artacho R, & Gimenez R (2006) Beneficial effects of green tea--a review. Journal of the American College of Nutrition 25(2):79-99. 56. Tamura M & Ochiai K (2012) Exploring the possible applications of catechin (gel) for oral care of the elderly and disabled individuals. Japanese Dental Science Review 48(2):126-134. 57. Ikigai H, Nakae T, Hara Y, & Shimamura T (1993) Bactericidal catechins damage the lipid bilayer. Biochim Biophys Acta 1147(1):132-136. 58. Steinmann J, Buer J, Pietschmann T, & Steinmann E (2013) Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol 168(5):1059-1073. 59. Gradisar H, Pristovsek P, Plaper A, & Jerala R (2007) Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J Med Chem 50(2):264-271. 60. Shen CL, et al. (2010) Green tea polyphenols mitigate bone loss of female rats in a chronic inflammation-induced bone loss model. The Journal of Nutritional Biochemistry 21(10):968-974. 61. Shen CL, et al. (2011) Green tea polyphenols attenuate deterioration of bone microarchitecture in female rats with systemic chronic inflammation. Osteoporosis International 22(1):327-337. 62. Maruyama T, et al. (2011) Supplementation of green tea catechins in dentifrices suppresses gingival oxidative stress and periodontal inflammation. Archives of Biochemistry and Biophysics 56(1):48-53. 63. Hosokawa Y, et al. (2010) Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival fibroblasts. The Journal of Nutritional Biochemistry 21(7):659-664. 64. Lee YL, et al. (2009) An extract of green tea, epigallocatechin-3-gallate, reduces periapical lesions by inhibiting cysteine-rich 61 expression in osteoblasts. Journal of Endodontics 35(2):206-211. 65. Dube A, Nicolazzo JA, & Larson I (2010) Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (−)-epigallocatechin gallate. European Journal of Pharmaceutical Sciences 41(2):219-225. 66. Qin Y, Wang HW, Karuppanapandian T, & Kim W (2010) Chitosan green tea polyphenol complex as a released control compound for wound healing. Chinese Journal of Traumatology 13(2):91-95. 67. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery 2(7):517-526. 68. Mundy G, et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446):1946-1949. 69. Seto H, et al. (2008) Topical administration of simvastatin recovers alveolar bone loss in rats. Journal of Periodontal Research 43(3):261-267. 70. Lee Y, et al. (2008) The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials 29(12):1940-1949. 71. Morris MS, et al. (2008) Injectable simvastatin in periodontal defects and alveolar ridges: pilot studies. Journal of Periodontology 79(8):1465-1473. 72. Souza MC, Marta • Silva, M. • Soledade, L. • Souza, A (2007) Thermal and kinetic study of statins. Journal of Thermal Analysis and Calorimetry 87:859-863. 73. Wong RWK & Rabie ABM (2003) Statin collagen grafts used to repair defects in the parietal bone of rabbits. British Journal of Oral and Maxillofacial Surgery 41(4):244-248. 74. Stein D, et al. (2005) Local simvastatin effects on mandibular bone growth and inflammation. Journal of Periodontology 76(11):1861-1870. 75. Ozec I, Kilic E, Gumus C, & Goze F (2007) Effect of local simvastatin application on mandibular defects. Journal of Craniofacial Surgery 18(3):546-550. 76. Ho MH, et al. (2011) Highly efficient release of lovastatin from poly(lactic-co-glycolic acid) nanoparticles enhances bone repair in rats. Journal of Orthopaedic Research 29(10):1504-1510. 77. Garrett IR, et al. (2007) Locally delivered lovastatin nanoparticles enhance fracture healing in rats. Journal of Orthopaedic Research 25(10):1351-1357. 78. Yoshii T, et al. (2010) A sustained release of lovastatin from biodegradable, elastomeric polyurethane scaffolds for enhanced bone regeneration. Tissue Engineering Part A 16(7):2369-2379. 79. Subramanian A, Vasanthan KS, Krishnan UM, & Sethuraman S (2011) Chitosan and its derivatives in clinical use and applications. Biodegradable Polymers in Clinical Use and Clinical Development, (John Wiley & Sons, Inc.), pp 111-135. 80. Hejazi R & Amiji M (2003) Chitosan-based gastrointestinal delivery systems. Journal of Controlled Release 89(2):151-165. 81. Tomihata K & Ikada Y (1997) In vitro and in vivo degradation of films of chitin and its deacetylated derivatives. Biomaterials 18(7):567-575. 82. No HK, Young Park N, Ho Lee S, & Meyers SP (2002) Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. International Journal of Food Microbiology 74(1–2):65-72. 83. Chatelet C, Damour O, & Domard A (2001) Influence of the degree of acetylation on some biological properties of chitosan films. Biomaterials 22(3):261-268. 84. Dodane V & Vilivalam VD (1998) Pharmaceutical applications of chitosan. Pharmaceutical Science and Technology Today 1(6):246-253. 85. Kim IY, et al. (2008) Chitosan and its derivatives for tissue engineering applications. Biotechnology Advances 26(1):1-21. 86. Illum L, Farraj N, & Davis S (1994) Chitosan as a novel nasal delivery system for peptide drugs. Pharmaceutical Research 11(8):1186-1189. 87. Mi FL, et al. (2002) Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. Journal of Biomedical Materials Research Part A 59(3):438-449. 88. Tran DL, et al. (2011) Some biomedical applications ofchitosan-based hybrid nanomaterials. Advances in Natural Sciences: Nanoscience and Nanotechnology 2(4). 89. Dash M, Chiellini F, Ottenbrite RM, & Chiellini E (2011) Chitosan—A versatile semi-synthetic polymer in biomedical applications. Progress in Polymer Science 36(8):981-1014. 90. Xu C, Lei C, Meng L, Wang C, & Song Y (2012) Chitosan as a barrier membrane material in periodontal tissue regeneration. Journal of Biomedical Materials Research Part B 100(5):1435-1443. 91. Kuo SM, Chang SJ, Chen TW, & Kuan TC (2006) Guided tissue regeneration for using a chitosan membrane: an experimental study in rats. Journal of Biomedical Materials Research Part A 76(2):408-415. 92. Helander IM, Nurmiaho Lassila EL, Ahvenainen R, Rhoades J, & Roller S (2001) Chitosan disrupts the barrier properties of the outer membrane of gram-negative bacteria. International Journal of Food Microbiology 71(2-3):235-244. 93. Choi BK, et al. (2001) In vitro antimicrobial activity of a chitooligosaccharide mixture against Actinobacillus actinomycetemcomitans and Streptococcus mutans. International Journal of Antimicrobial Agents 18(6):553-557. 94. Boateng JS, Matthews KH, Stevens HN, & Eccleston GM (2008) Wound healing dressings and drug delivery systems: a review. Journal of Pharmaceutical Sciences 97(8):2892-2923. 95. Boynuegri D, et al. (2009) Clinical and radiographic evaluations of chitosan gel in periodontal intraosseous defects: a pilot study. Journal of Biomedical Materials Research Part B 90(1):461-466. 96. Teng SH, Lee EJ, Wang P, Shin DS, & Kim HE (2008) Three-layered membranes of collagen/hydroxyapatite and chitosan for guided bone regeneration. Journal of Biomedical Materials Research Part B 87B(1):132-138. 97. Ilium L (1998) Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Research 15(9):1326-1331. 98. Wang JJ, et al. (2011) Recent advances of chitosan nanoparticles as drug carriers. International Journal of Nanomedicine 6:765-774. 99. Nagpal K, Singh SK, & Mishra DN (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chemical and Pharmaceutical Bulletin 58(11):1423-1430. 100. Bhattarai N, Gunn J, & Zhang M (2010) Chitosan-based hydrogels for controlled, localized drug delivery. Advanced Drug Delivery Reviews 62(1):83-99. 101. Krajewska B (2005) Membrane-based processes performed with use of chitin/chitosan materials. Separation and Purification Technology 41(3):305-312. 102. Vinsova J & Vavrikova E (2008) Recent advances in drugs and prodrugs design of chitosan. Current Pharmaceutical Design 14(13):1311-1326. 103. Masotti A & Ortaggi G (2009) Chitosan micro- and nanospheres: fabrication and applications for drug and DNA delivery. Mini Reviews in Medicinal Chemistry 9(4):463-469. 104. Ren D, Yi H, Wang W, & Ma X (2005) The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydrate Research 340(15):2403-2410. 105. Jain JP, Yenet Ayen W, Domb AJ, & Kumar N (2011) Biodegradable polymers in drug delivery. Biodegradable Polymers in Clinical Use and Clinical Development, (John Wiley & Sons, Inc.), pp 1-58. 106. Akman AC, Tığlı RS, Gumuşderelioğlu M, & Nohutcu RM (2010) bFGF-loaded HA-chitosan: A promising scaffold for periodontal tissue engineering. Journal of Biomedical Materials Research Part A 92A(3):953-962. 107. Park YJ, et al. (2000) Platelet derived growth factor releasing chitosan sponge for periodontal bone regeneration. Biomaterials 21(2):153-159. 108. Han KH, et al. (2007) The effects of chitosan-tetracycline membrane on periodontal regeneration of one-wall intrabony defects in beagle dogs. Key Engineering Materials 342-343:361-364. 109. Mi FL, et al. (2001) Fabrication and characterization of a sponge-like asymmetric chitosan membrane as a wound dressing. Biomaterials 22(2):165-173. 110. Zeng X & Ruckenstein E (1996) Control of pore sizes in macroporous chitosan and chitin membranes. Industrial and Engineering Chemistry Research 35(11):4169-4175. 111. Ma Y, Zhou T, & Zhao C (2008) Preparation of chitosan–nylon-6 blended membranes containing silver ions as antibacterial materials. Carbohydrate Research 343(2):230-237. 112. Gumuşderelioğlu M & Agi P (2004) Adsorption of concanavalin A on the well-characterized macroporous chitosan and chitin membranes. Reactive and Functional Polymers 61(2):211-220. 113. Liu YL, Su YH, Lee KR, & Lai JY (2005) Crosslinked organic–inorganic hybrid chitosan membranes for pervaporation dehydration of isopropanol–water mixtures with a long-term stability. Journal of Membrane Science 251(1–2):233-238. 114. Beppu MM, Vieira RS, Aimoli CG, & Santana CC (2007) Crosslinking of chitosan membranes using glutaraldehyde: Effect on ion permeability and water absorption. Journal of Membrane Science 301(1–2):126-130. 115. Anjali Devi D, Smitha B, Sridhar S, & Aminabhavi TM (2005) Pervaporation separation of isopropanol/water mixtures through crosslinked chitosan membranes. Journal of Membrane Science 262(1–2):91-99. 116. Goncalves VL, Laranjeira MCM, Favere VT, & Pedrosa RC (2005) Effect of crosslinking agents on chitosan microspheres in controlled release of diclofenac sodium. Polimeros 15:6-12. 117. Ho MH, Hsieh CC, Hsiao SW, & Van Hong Thien D (2010) Fabrication of asymmetric chitosan GTR membranes for the treatment of periodontal disease. Carbohydrate Polymers 79(4):955-963. 118. Madihally SV & Matthew HWT (1999) Porous chitosan scaffolds for tissue engineering. Biomaterials 20(12):1133-1142. 119. Zhong Z, et al. (2007) The preparation and antioxidant activity of the sulfanilamide derivatives of chitosan and chitosan sulfates. Bioorganic and Medicinal Chemistry 15(11):3775-3782. 120. Kast CE, Frick W, Losert U, & Bernkop Schnurch A (2003) Chitosan-thioglycolic acid conjugate: a new scaffold material for tissue engineering? International Journal of Pharmaceutics 256(1–2):183-189. 121. Rekha MR & Sharma CP (2009) Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. Journal of Controlled Release 135(2):144-151. 122. Kotze AF, et al. (1999) Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). European Journal of Pharmaceutics and Biopharmaceutics 47(3):269-274. 123. Chen XG, Lee CM, & Park HJ (2003) O/W emulsification for the self-aggregation and nanoparticle formation of linoleic acid modified chitosan in the aqueous system. Journal of Agricultural and Food Chemistry 51(10):3135-3139. 124. Chae SY, Son S, Lee M, Jang MK, & Nah JW (2005) Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier. Journal of Controlled Release 109(1-3):330-344. 125. Du J & Hsieh YL (2007) PEGylation of chitosan for improved solubility and fiber formation via electrospinning. Cellulose 14(6):543-552. 126. Mphahlele R (2005) Drug release properties of cross-linked N-carboxymethylated chitosan wafers (Tshwane University of Technology). 127. Nunthanid J, et al. (2004) Characterization of chitosan acetate as a binder for sustained release tablets. Journal of Controlled Release 99(1):15-26. 128. Fei C, Guangsheng L, Weiwei Y, & Yujin W (2005) Preparation and adsorption ability of polysulfone microcapsules containing modified chitosan gel. 10(1-5):535-541. 129. Kogan G, et al. (2004) Antioxidant and antimutagenic activity of N-(2-carboxyethyl)chitosan. Toxicol Appl Pharmacol 201(3):303-310. 130. Chen T, Kumar G, Harris MT, Smith PJ, & Payne GF (2000) Enzymatic grafting of hexyloxyphenol onto chitosan to alter surface and rheological properties. Biotechnology and Bioengineering 70(5):564-573. 131. Sousa F, Guebitz GM, & Kokol V (2009) Antimicrobial and antioxidant properties of chitosan enzymatically functionalized with flavonoids. Process Biochemistry 44(7):749-756. 132. Itzincab Mejia L, Lopez Luna A, Gimeno M, Shirai K, & Barzana E (2013) Enzymatic grafting of gallate ester onto chitosan: evaluation of antioxidant and antibacterial activities. International Journal of Food Science & Technology 48(10):2034-2041. 133. Lei F, Liu F, Yuan F, & Gao Y (2014) Impact of chitosan–EGCG conjugates on physicochemical stability of β-carotene emulsion. Food Hydrocolloids 39(0):163-170. 134. Liu J, Lu Jf, Kan J, Tang Yq, & Jin Ch (2013) Preparation, characterization and antioxidant activity of phenolic acids grafted carboxymethyl chitosan. International Journal of Biological Macromolecules 62(0):85-93. 135. Lei F, Wang X, Liang C, Yuan F, & Gao Y (2014) Preparation and functional evaluation of chitosan-EGCG conjugates. Journal of Applied Polymer Science 131(3):n/a-n/a. 136. Curcio M, et al. (2009) Covalent insertion of antioxidant molecules on chitosan by a free radical grafting procedure. Journal of Agricultural and Food Chemistry 57(13):5933-5938. 137. Lee DS & Je JY (2013) Gallic acid-grafted-chitosan inhibits foodborne pathogens by a membrane damage mechanism. Journal of Agricultural and Food Chemistry 61(26):6574-6579. 138. Tang DW, et al. (2013) Characterization of tea catechins-loaded nanoparticles prepared from chitosan and an edible polypeptide. Food Hydrocolloids 30(1):33-41. 139. Socrates G (1994) Infrared Characteristic Group Frequencies (second ed.) 140. Caroni ALPF, de Lima CRM, Pereira MR, & Fonseca JLC (2012) Tetracycline adsorption on chitosan: A mechanistic description based on mass uptake and zeta potential measurements. Colloids and Surfaces B: Biointerfaces 100(0):222-228. 141. Marcazzan M, Vianello F, Scarpa M, & Rigo A (1999) An ESR assay for alpha-amylase activity toward succinylated starch, amylose and amylopectin. Journal of Biochemical and Biophysical Methods 38(3):191-202. 142. Parker SF, Williams KPJ, Meehan P, Adams MA, & Tomkinson J (1994) Analysis of carbon black-filled polymers by vibrational spectroscopy. Applied Spectroscopy 48(6):669-673. 143. Kumar A, Rout S, Sahoo DK, & Kumar BVVR (2013) Synthesis and biological evaluation of new 4-bromo-3, 5-diaryl-1-phenyl-2- pyrazoline derivatives as antioxidant and anti-inflammatory agents. International Journal of Research and Development in Pharmacy and Life Sciences 2 (2):349-354. 144. Kaushal R, Kumar N, Chaudhary A, Arora S, & Awasthi P (2014) Synthesis, spectral characterization, and antiproliferative studies of mixed ligand titanium complexes of adamantylamine. Bioinorganic Chemistry and Applications 2014:12. 145. Zhu X, Chian KS, Chan Park MB, & Lee ST (2005) Effect of argon-plasma treatment on proliferation of human-skin-derived fibroblast on chitosan membrane in vitro. Journal of Biomedical Materials Research Part A 73(3):264-274. 146. Lopez Perez PM, da Silva RMP, Serra C, Pashkuleva I, & Reis RL (2010) Surface phosphorylation of chitosan significantly improves osteoblast cell viability, attachment and proliferation. Journal of Materials Chemistry 20(3):483-491. 147. Lopez Perez PM, Marques AP, Silva RMPd, Pashkuleva I, & Reis RL (2007) Effect of chitosan membrane surface modification via plasma induced polymerization on the adhesion of osteoblast-like cells. Journal of Materials Chemistry 17(38):4064-4071. 148. Kaelble DH & Moacanin J (1977) A surface energy analysis of bioadhesion. Polymer 18(5):475-482. 149. Lai SM, Lee WL, Chang YM, & Liaw WC (2008) Preparative Isolation of catechins from green tea powders using intermediate polar adsorbent. Journal of Liquid Chromatography and Related Technologies 32(2):293-311. 150. Morandini ACF, et al. (2009) Differential production of macrophage inflammatory protein-1α, stromal-derived factor-1, and IL-6 by human cultured periodontal ligament and gingival fibroblasts challenged with lipopolysaccharide from p. gingivalis. Journal of Periodontology 81(2):310-317. 151. Nebel D, Arvidsson J, Lillqvist J, Holm A, & Nilsson BO (2013) Differential effects of LPS from Escherichia coli and Porphyromonas gingivalis on IL-6 production in human periodontal ligament cells. Acta Odontologica Scandinavica 71(3-4):892-898. 152. Hwang SM, Chen CY, Chen SS, & Chen JC (2000) Chitinous materials inhibit nitric oxide production by activated RAW 264.7 macrophages. Biochemical and Biophysical Research Communications 271(1):229-233. 153. Lian JB & Stein GS (1992) Concepts of osteoblast growth and differentiation: basis for modulation of bone cell development and tissue formation. Critical Reviews in Oral Biology and Medicine 3(3):269-305. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57177 | - |
dc.description.abstract | 可吸收性再生膜因具有生物相容性及促進組織修復能力,已被廣泛運用於牙科再生手術。本研究利用生物可降解性材料-幾丁聚醣(Chitosan)作為再生膜基材,製備出緻密的三層膜結構,表層接枝兒茶素(EGCG),而中間層則作為洛伐他汀(Lovastatin)的釋放載體。進行微拉伸測試、FTIR-ATR分析、鹼性磷酸酶(ALPase)活性測試、細胞毒性、貼附及增生等試驗。結果顯示再生膜厚度為0.17 mm,強度為1.67MPa,為目前臨床使用膠原蛋白再生膜的2倍。以丁二酸酐(succinic anhydride)修飾EGCG後透過EDC/NHS交聯於幾丁聚醣再生膜之表面,FTIR檢測出在1215 cm-1處的芳香氫氧基吸收峰,顯示EGCG以化學鍵結方式接枝於幾丁聚醣再生膜表面。細胞測試結果顯示,以14mM EGCG濃度進行接枝反應,能增加幾丁聚醣再生膜的細胞親和性,促進人類牙齦纖維母細胞貼附及增生。而再生膜中間層搭載1mg/cm2 lovastatin,其以滲透方式釋放至磷酸緩衝液中,能達到21天的長時間釋放,與人類胚胎上顎間質細胞共同培養後會先抑制其增生,並且在第7天時提升骨分化酵素ALPase的活性,促進細胞進行骨分化。表面接枝EGCG並搭載lovastatin的幾丁聚醣再生膜能促進傷口癒合及骨質新生,對於牙周組織的修復及再生極具潛力。 | zh_TW |
dc.description.abstract | Biodegradable membrane for guided tissue regeneration (GTR) has been utilized as a barrier in periodontal surgery to promote tissue healing. As epigallocatechin-3-gallate (EGCG) can reduce inflammation and lovastatin can increase bone regeneration, the aim of this study was to prepare a functional tri-layer chitosan membrane to enhance the healing of periodontal tissue. EGCG was grafted on the outer surface of the top layer and lovastatin was embedded in the middle layer for controlled release. EGCG was grafted on the outer surface using ethyl (dimethylaminopropyl) carbodiimide/ N-hydroxysuccinimide (EDC/NHS) reaction. The microtensile strength of chitosan membrane was measured and Fourier transform infrared spectroscopy (FTIR) was used for surface characterization. UV–vis spectroscopy was used to quantify lovastatin release. Cell adhesion, proliferation, nitric oxide, and alkaline phosphatase (ALPase) assay were evaluated for biological function. The microtensile strength of fabricated membrane was 1.67 MPa which was superior to commercial collagen GTR membrane. FTIR spectra indicated EGCG was grafted on membrane as the 1215 cm-1 peak corresponding to aromatic C-O was identified. The chitosan membrane grafted by 14mM EGCG could increase the adhesion and proliferation of human gingival fibroblasts to promote the tissue wound healing. The membrane which loaded with 1mg/cm2 lovastatin could release for 21 days, and inhibited the cell proliferation at 5th day followed by increasing the ALPase activity at 7th day in Homo sapiens palatal mesenchymal cells. The chitosan membrane can promote bone activity and wound healing. It has potential to be used in GTR surgery for enhancing periodontal repair. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:36:59Z (GMT). No. of bitstreams: 1 ntu-103-R01450004-1.pdf: 3464399 bytes, checksum: f5ba75f44d2f74445f8118b32d3cf1f3 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 口試委員審定書 ................................ ................................ ................................ ............... I
誌謝 ................................ ................................ ................................ ................................ .. II 中文 摘要 ................................ ................................ ................................ ........................ III 英文摘要 ................................ ................................ ................................ ........................ IV 第一章 前言 ................................ ................................ ................................ .................... 1 第二章 文獻回顧 ................................ ................................ ................................ ............ 2 2.1 牙周病及治療 牙周病及治療 牙周病及治療 牙周病及治療 牙周病及治療 牙周病及治療 ................................ ................................ ................................ ................ 2 2.1.1 病因 ................................ ................................ ................................ ..................... 2 2.1.3 牙周病治療 ................................ ................................ ................................ ...... 3 2.1.4 引導組織再生手術 ................................ ................................ .......................... 3 2.2 再生膜 ................................ ................................ ................................ ........................ 4 2.2.1 再生膜材料 ................................ ................................ ................................ ...... 4 2.2.2 再生膜製備方法 ................................ ................................ .............................. 4 2.2.3 再生膜作為藥物釋放載體 ................................ ................................ .............. 5 2.3 牙周病之發炎及傷口癒合 ................................ ................................ ........................ 7 2.3.1 兒茶素 ................................ ................................ ................................ .............. 8 2.4 Statin 2.4 Statin ................................ ................................ ................................ ........................... 8 2.4.1 Lovastatin 2.4.1 Lovastatin2.4.1 Lovastatin 2.4.1 Lovastatin2.4.1 Lovastatin 於牙周骨缺陷修復之應用 ................................ ............................ 9 2.5 幾丁聚醣 ................................ ................................ ................................ .................... 9 2.5.1 幾丁聚醣於生物可降解性再膜之應用 ................................ ..................... 11 2.5.2 幾丁聚醣藥物載體於骨質新生之應用 ................................ ......................... 11 2.5.3 幾丁聚醣薄膜合成方法 ................................ ................................ ................ 13 VI 2.5.4 幾丁聚醣化學改 質於生醫材料應用 ................................ ............................ 14 2.5.5 綠茶多酚應用於幾丁聚醣改質 ................................ ................................ .... 17 第三章 材料與方法 ................................ ................................ ................................ ...... 19 3.1 實驗藥品 ................................ ................................ ................................ .................. 19 3.2 實驗儀器 ................................ ................................ ................................ .................. 20 3.3 實驗流程圖 ................................ ................................ ................................ .............. 22 3.4 製備表面接枝 EGCG 並搭載 lov astatinastatin 之幾丁聚醣再生膜 (EGCG (EGCG -LovaLova Lova-CS CS CS tri -layer membrane) layer membrane)layer membrane)layer membrane) layer membrane) layer membrane)layer membrane) layer membrane) ................................ ................................ ................................ ........ 23 3.4.1 製備幾丁聚醣再生膜 ................................ ................................ .................... 23 3.4.2 製備搭載 LovastatinLovastatin LovastatinLovastatin 之幾丁聚醣薄膜 ................................ ........................ 23 3.4.3 製備表面接枝 EGCG 之幾丁聚醣薄膜 ................................ ...................... 24 3.4.4 組裝三層膜 ................................ ................................ ................................ .... 26 3.5 再生膜結構及強度分析 ................................ ................................ .......................... 26 3.5.1 掃描式電子顯微鏡 ................................ ................................ ........................ 26 3.5.2 微拉伸強度測試 ................................ ................................ ........................... 27 3.6 EGCG 3.6 EGCG3.6 EGCG接枝結果分析 (FTIR (FTIR(FTIR(FTIR-ATR)ATR) ................................ ................................ .......... 27 3.7 Lovastatin 3.7 Lovastatin3.7 Lovastatin 3.7 Lovastatin 3.7 Lovastatin3.7 Lovastatin 3.7 Lovastatin釋放分析 (UV (UV-vis) ................................ ................................ .................. 28 3.8 細胞培養 ................................ ................................ ................................ .................. 28 3.8.1 解凍細胞 ................................ ................................ ................................ ........ 28 3.8.2 繼代培養 ................................ ................................ ................................ ........ 29 3.8.3 冷凍細胞 ................................ ................................ ................................ ........ 29 3.9 接枝 EGCG 幾丁聚醣再生膜之細 胞活性分析 ................................ ..................... 30 3.9.1 細胞貼附及增生測試 (MTT assay) (MTT assay) (MTT assay) (MTT assay)(MTT assay) ................................ ............................. 30 3.9.2 細胞型態觀察 ................................ ................................ ................................ 31 3.9.3 抗發炎測試 (NO a (NO a ssay) ssay)ssay) ................................ ................................ ................ 31 VII 3.10 搭載 lovastatin 幾丁聚醣再生膜之細胞活性測試 ................................ ............... 32 3.10.1 細胞毒性測試 (MTT assay) (MTT assay) (MTT assay) (MTT assay)(MTT assay) ................................ ................................ ....... 32 3.10.2 鹼性磷酸酶活測試 (ALPase assay) (ALPase assay)(ALPase assay)(ALPase assay)(ALPase assay) (ALPase assay) (ALPase assay) (ALPase assay)(ALPase assay)(ALPase assay) ................................ ...................... 33 3.11 3.11 統計分析 ................................ ................................ ................................ ............... 35 第四章 結果 ................................ ................................ ................................ .................. 36 4.1 EGCG 4.1 EGCG4.1 EGCG-LovaLova -CS 再生膜成品 再生膜成品 ................................ ................................ .................. 36 4.2 EGCG 4.2 EGCG4.2 EGCG-LovaLova -CS 再生膜結構 再生膜結構 (SEM) ................................ ................................ ...... 36 4.3 再生膜微拉伸強度測試 (microtensile test) (microtensile test) (microtensile test) (microtensile test)(microtensile test) ................................ ........................... 36 4.4 EGCG 4.4 EGCG4.4 EGCG接枝再生膜之 FTIRFTIRFTIRFTIR圖譜 (FTIR(FTIR(FTIR(FTIR(FTIR-ATR)ATR)ATR)ATR) ................................ ..................... 37 4.5 再生膜之 lovastatin 釋放模式 (UV (UV-vis) ................................ ................................ . 38 4.6 EGCG 4.6 EGCG4.6 EGCG接枝再生膜之細胞測試 ................................ ................................ .............. 39 4.6.1 EGCG 4.6.1 EGCG4.6.1 EGCG接枝再生膜之細胞貼附性 (cell adhesion assay) (cell adhesion assay)(cell adhesion assay) (cell adhesion assay) (cell adhesion assay) (cell adhesion assay)(cell adhesion assay) (cell adhesion assay)(cell adhesion assay) ............................. 39 4.6.2 EGCG 4.6.2 EGCG4.6.2 EGCG接枝再生膜之細胞增能力 (cell proliferation assay) (cell proliferation assay)(cell proliferation assay) (cell proliferation assay) (cell proliferation assay) (cell proliferation assay) (cell proliferation assay) (cell proliferation assay) (cell proliferation assay) (cell proliferation assay)(cell proliferation assay) ................... 40 4.6.3 EGCG 4.6.3 EGCG4.6.3 EGCG接枝再生膜之抗發炎能力 ................................ ................................ 40 4.7 幾丁聚醣再生膜 LovastatinLovastatinLovastatin Lovastatin 釋放之細胞測試 ................................ ....................... 41 4.7.1 Lovastatin 4.7.1 Lovastatin4.7.1 Lovastatin 4.7.1 Lovastatin4.7.1 Lovastatin 釋放對細胞活性之影響 (cell viability assay) (cell viability assay)(cell viability assay) (cell viability assay) (cell viability assay) (cell viability assay)(cell viability assay)(cell viability assay)(cell viability assay)(cell viability assay) (cell viability assay)(cell viability assay) ............................ 41 4.7.2 Lovastatin 4.7.2 Lovastatin4.7.2 Lovastatin 4.7.2 Lovastatin4.7.2 Lovastatin 釋放對 ALPaseALPaseALPaseALPaseALPaseALPase活性影響 (ALPase activity assay) (ALPase activity assay)(ALPase activity assay)(ALPase activity assay)(ALPase activity assay) (ALPase activity assay) (ALPase activity assay)(ALPase activity assay) (ALPase activity assay) (ALPase activity assay)(ALPase activity assay) (ALPase activity assay) (ALPase activity assay)(ALPase activity assay).................... 42 第五章 討論 ................................ ................................ ................................ .................. 56 第六章 結論 ................................ ................................ ................................ .................. 61 參考文獻 ................................ ................................ ................................ ........................ 62 | |
dc.language.iso | zh-TW | |
dc.title | 表面接枝兒茶素及釋放控制洛伐他汀之幾丁聚醣再生膜對牙周組織再生及癒合之促進 | zh_TW |
dc.title | Chitosan Membrane Grafted with Epigallocatechin-3-Gallate and Controlled Release of Lovastatin for Periodontal Tissue Regeneration | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 李伯訓(Bor-Shiunn Lee) | |
dc.contributor.oralexamcommittee | 王大銘(Da-Ming Wang) | |
dc.subject.keyword | 牙周病,再生膜,幾丁聚醣,EGCG,lovastatin,組織再生, | zh_TW |
dc.subject.keyword | periodontal disease,GTR membrane,chitosan,EGCG,lovastatin,tissue regeneration, | en |
dc.relation.page | 73 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-07-31 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 3.38 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。